1-855-378-42281-855-378-4228
One of the out-patient rehabilitation options for people in Towanda who are battling with opioid dependence and addiction is opioid maintenance therapy. Some centers and doctors are certified to dispense specific medications to opioid addicted individuals, many of which are opioid-based themselves and are addiction. In low enough doses the client does not experience high feelings but also does not experience acute cravings and isn't experiencing opioid withdrawal. Methadone is the first medication administered for this reason, but there are a few more options currently to choose from.
Methadone is an opiate and is meant to be taken at an out-patient medical center licensed to dispense the med, that is taken on a daily basis as a pill or liquid. The cost of the drug is around $150 per month. Buprenorphine is also an opioid-based med, and is a pill often taken every other day. But unlike Methadone that can only be given in highly well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately $300 a month for the generic version of the medication. There is also a type of buprenorphine containing the drug naloxone, which is a drug which blocks the effects of opiates. An individual taking this formulation, AKA Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and costs about $450 per month. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other drugs mentioned here it is an opioid blocker and is not an opiate. A person has the choice to take this drug as a monthly shot, which is called Vivitrol. As an opioid blocker, it prevents a person from experience high feelings from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 per month.
For All Alcohol and Drug Rehabilitation Programs In Towanda, Click Here.
